hepatitis B
-
Labcorp launches reflex testing to improve hepatitis D detection in US
Labcorp estimates that between 70,000 and 150,000 people in the US are living with active HDV infection, while fewer than 20% of patients who test positive for hepatitis B are tested for hepatitis D.
-
AusperBio raises US$120M to advance Hepatitis B therapies toward functional cure
AusperBio will use a significant portion of the proceeds to advance AHB 137, an antisense oligonucleotide therapy for CHB, through its Phase III registrational programme and toward potential commercialisation.
-
GSK gains first global approval for Bepirovirsen as Japan clears new hepatitis B functional cure
The antisense oligonucleotide (ASO) medicine, which GSK will market in Japan as Hibsago, is approved for adults with hepatitis B who meet specified viral markers.
-
AusperBio begins patient dosing in trial of Hepatitis B siRNA candidate AHB-171
The latest milestone advances the company’s second clinical-stage therapeutic candidate and marks the first clinical programme built using its proprietary Au-HALO™ liver-targeting delivery technology and siRNA platform.
-
Cameroon advances triple-elimination goals with national hepatitis survey of 10,000 women
The survey will involve about 10,000 pregnant women across all 10 regions of Cameroon.
-
Africa CDC releases new toolkit to combat hepatitis B burden
Africa CDC developed the resource through its Hepatitis B Group of Experts, in collaboration with the Centre for Operational Research on Hepatitis B, HEPSANET and the Society for the Study of Liver Disease in Africa.
-
GSK’s Bepirovirsen under EMA review for chronic hepatitis B
Chronic hepatitis B affects an estimated 3.2 million people in Europe alone and more than 250 million people globally.